Veradigm (MDRX) Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Which has preferable valuation and earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.33	N/A	N/A	N/A
Omnicell	$1.11B	1.26	$12.53M	$0.46	65.09

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 1.87% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.87%	4.60%	2.56%

Does the media favor MDRX or OMCL?

In the previous week, Veradigm had 3 more articles in the media than Omnicell. MarketBeat recorded 3 mentions for Veradigm and 0 mentions for Omnicell. Omnicell's average media sentiment score of 1.88 beat Veradigm's score of 0.40 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Omnicell	Very Positive

Do institutionals & insiders hold more shares of MDRX or OMCL?

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, MDRX or OMCL?

Veradigm has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Do analysts rate MDRX or OMCL?

Veradigm presently has a consensus target price of $13.00, suggesting a potential upside of 176.60%. Omnicell has a consensus target price of $44.83, suggesting a potential upside of 49.74%. Given Veradigm's higher possible upside, research analysts plainly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Omnicell beats Veradigm on 9 of the 13 factors compared between the two stocks.